pubs.notes | affiliation: Wymann, MP (Reprint Author), Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland. Bohnacker, Thomas; Beaufils, Florent; Melone, Anna; Rageot, Denise; Sele, Alexander M.; Cmiljanovic, Vladimir; Cmiljanovic, Natasa; Wymann, Matthias P., Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland. Prota, Andrea E.; Bargsten, Katja; Steinmetz, Michel O., Paul Scherrer Inst, Dept Biol & Chem, Lab Biomol Res, CH-5232 Villigen, Switzerland. Burke, John E., Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 2Y2, Canada. Inglis, Alison J.; Williams, Roger L., MRC Lab Mol Biol, Cambridge CB2 2QH, England. Aher, Amol; Akhmanova, Anna, Univ Utrecht, Cell Biol, Fac Sci, NL-3584 CH Utrecht, Netherlands. Fernando Diaz, J., CIB Ctr Invest Biol, Madrid 28040, Spain. Beaufils, Florent; Cmiljanovic, Vladimir; Cmiljanovic, Natasa; Fabbro, Doriano, PIQUR Therapeut AG, CH-4057 Basel, Switzerland. Zvelebil, Marketa, Inst Canc Res, London SW3 6JB, England. Bargsten, Katja, Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland. article-number: 14683 keywords-plus: METASTATIC BREAST-CANCER; ADVANCED SOLID TUMORS; IN-VITRO; PI3-KINASE INHIBITOR; KINASE INHIBITOR; DOSE-ESCALATION; CELL-DEATH; PHASE-I; NVP-BKM120; BKM120 research-areas: Science & Technology - Other Topics web-of-science-categories: Multidisciplinary Sciences author-email: [email protected] researcherid-numbers: Wymann, Matthias/C-3227-2008 Diaz, J. Fernando/U-3532-2017 orcid-numbers: Wymann, Matthias/0000-0003-3349-4281 Diaz, J. Fernando/0000-0003-2743-3319 Burke, John/0000-0001-7904-9859 Aher, Amol/0000-0002-5283-5259 Zvelebil, Marketa/0000-0001-8018-5591 Steinmetz, Michel/0000-0001-6157-3687 Bohnacker, Thomas/0000-0001-5769-4478 funding-acknowledgement: Swiss Commission for Technology and Innovation (CTI) by PFLS-LS [14032.1, 15811.2, 17241.1]; Stiftung fur Krebsbekampfung grant [341]; Swiss National Science Foundation [310030_153211, 316030_133860, 310030B_138659, 31003A_166608]; European Union [675392, BIO2013-42984-R, S2010/BMD-2457 BIPEDD2]; MRC [U105184308]; British Heart Foundation [PG/11/109/29247]; Medical Research Council [MC_U105184308] funding-text: We thank P. Hebeisen, B. Giese, A. Pfaltz, E. Jackson and J. B. Langlois for advice, discussion and synthesis of chemical precursors and compounds; M. Neubauer and D. Hausinger for chemical structure determination; Pascal Lorenz and the BioOptics Facility for support with microscopy; Robert Ivanek for bioinformatics support and R. Sriramaratnam for editorial help. We are grateful to G. Zaman and the NTRC team for help and expertise with high-content screening assays. This work was supported by the Swiss Commission for Technology and Innovation (CTI) by PFLS-LS grants 14032.1, 15811.2 and 17241.1; the Stiftung fur Krebsbekampfung grant 341, Swiss National Science Foundation grants 310030_153211 and 316030_133860 (to M.P.W.), and 310030B_138659 and 31003A_166608 (to M.O.S.); in part by European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement 675392, and grants BIO2013-42984-R (Ministerio de Economia y Competitividad), S2010/BMD-2457 BIPEDD2 (Comunidad Auto noma de Madrid) to J.F.D.; and by the MRC to R.L.W. (U105184308). number-of-cited-references: 47 times-cited: 13 usage-count-last-180-days: 2 usage-count-since-2013: 9 journal-iso: Nat. Commun. doc-delivery-number: EN2IQ unique-id: ISI:000395833600001 oa: gold da: 2018-08-03 | |